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MHCclass I-restricted epitopes, which carry a tumor-specific
mutation resulting in improved MHC binding affinity, are pre-
ferred T cell receptor targets in innovative adoptive T cell ther-
apies. However, T cell therapy requires efficient generation of
the selected epitope. How such mutations may affect protea-
some-mediated antigen processing has so far not been studied.
Therefore, we analyzed by in vitro experiments the effect on
antigenprocessing and recognitionof aT210Mexchange,which
previously had been introduced into the melanoma gp100209–217
tumor epitope to improve the HLA-A*02:01 binding and its
immunogenicity. A quantitative analysis of the main steps of
antigen processing shows that the T210M exchange affects pro-
teasomal cleavage site usage within the mutgp100201–230 poly-
peptide, leading to the generation of an unique set of cleavage
products. The T210M substitution qualitatively affects the pro-
teasome-catalyzed generation of spliced and non-spliced pep-
tides predicted to bind HLA-A or -B complexes. The T210M
substitution also induces an enhanced production of the
mutgp100209–217 epitope and its N-terminally extended pep-
tides. The T210M exchange revealed no effect on ERAP1-medi-
ated N-terminal trimming of the precursor peptides. However,
mutant N-terminally extended peptides exhibited significantly
increased HLA-A*02:01 binding affinity and elicited CD8 T
cell stimulation in vitro similar to the wtgp100209–217 epitope.
Thus, our experiments demonstrate that amino acid exchanges
within an epitope can result in the generation of an altered pep-
tide poolwith new antigenic peptides and in awiderCD8Tcell
response also towards N-terminally extended versions of the
minimal epitope.
Protein degradation by the ubiquitin-proteasome system
plays an important role in regulating cellular protein homeo-
stasis. Concomitant with the degradation of proteins, the 20S
proteasome, which is the catalytic core of the ubiquitin-protea-
some system, generates peptides of 8–12 amino acids in length
or N-terminally extended precursor peptides that, after trim-
ming by endoplasmic reticulum (ER)3 resident amino pepti-
dases (ERAPs), can bindMHC class I molecules in the ER to be
presented at the cell surface to CD8 T cells for immune rec-
ognition. These antigenic peptides can be produced by the pro-
teasome by normal peptide-bond hydrolysis or by proteasome-
catalyzed peptide splicing. The latter reaction generates
peptides that have a different sequence than the original anti-
gen, and it can occur by binding fragments of a single molecule
(cis proteasome-catalyzed peptide splicing) or of two distinct
molecules (trans proteasome-catalyzed peptide splicing) (1–4).
In vitro experiments performed with purified 20S protea-
somes were shown to closely reflect the in vivo situation, mak-
ing it an ideal platform to study the generation of non-spliced
and spliced antigenic peptides in vitro (1, 5–11). Under ideal
conditions the 20S proteasome exists in two isoforms, i.e. the
standard 20S proteasome (s-proteasomes) with the active site
subunits 1, 2, and 5 and the 20S immunoproteasomes
(i-proteasomes) with the inducible active site subunits 1i, 2i,
and 5i. Constitutive expression of true i-proteasomes appears
to be restricted to a small number ofmainly immune cells like B
or T cells. In contrast, the expression of so-called intermediate-
type proteasomes containing both standard- and immuno-ac-
tive subunits appears to be more frequent. Intermediate-type
proteasomes are expressed in most tumor cells and in many
tissues of the humanbodyunder normal physiological nutrition
and growth conditions (12). It has been recently shown that the
active subunit composition of 20S proteasomes in principle
does not affect the quality of proteasome-generated peptides (5,
13, 14). Nevertheless, proteasomal subunit composition can
strongly affect cleavage site usage within a given substrate and
hence the relative quantity of non-spliced or spliced peptides
produced. Such quantitative differences in the generation of
cleavage products can strongly affect cell surface presentation
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ofMHC class I-peptide complexes and in consequence the effi-
cacy of a peptide-specific CD8 T cell response (5, 13–15).
Although sequence requirements for proteasomal cleavage
site usage are difficult to predict, there exists frequent evidence
that seemingly minor alteration in the primary sequence of a
protein substrate can have an impact on proteasomal pro-
cessing and thereby positively or negatively affecting the liber-
ation of antigenic peptides and concomitantly the CD8T cell-
dependent immune response (7, 10, 16).Mutations flanking the
C-terminal residue of an antigenic peptide were shown to infer
negatively as well as positively with the generation and presen-
tation of the respective epitopes (17–20). There exist also
examples of amino acid exchanges occurring within an epitope
sequence that introduce a strong proteasomal cleavage site and
that consequently leads to a suppression of epitope generation
(16, 21). With respect of innovative adoptive T cell therapies,
tumor-specific mutated epitopes with enhanced MHC class I
binding affinity are of particular interest and are used for the
cloning of tumor-specific T cell receptors for T cell therapy
(22). Also, vaccination against the tumor with longer polypep-
tides requiring proteasomal processing has been shown to
increase the anti-tumor immune response (23).
Although the success of T cell therapies strongly depends on
efficient proteasomal processing of such mutant epitopes,
almost no information exists on how such amino acid
exchanges within a tumor epitope, which enhance binding
affinity to the MHC class I molecules, affect proteasomal pro-
cessing.We, therefore, analyzed with the help of in vitro exper-
iments the effect on proteasome-mediated antigen processing
of a T210M substitution, which was introduced into the mela-
noma gp100209–217 tumor epitope at the HLA-A*02:01 binding
anchor position to improve its immunogenicity (24). This first
comprehensive quantitative study of in vitro tumor antigen
generation and presentation revealed that the T210M substitu-
tion within the mutgp100201–230 polypeptide substrate induces
alteration in proteasomal cleavage site usage, epitope presenta-
tion, and recognition by CD8 T cells. It also leads to the gen-
eration of an altered antigenic peptide pool, which may be of
particular relevance when longer synthetic polypeptides are
used for tumor vaccination (23).
Experimental Procedures
Cell Cultures—Lymphoblastoid cell lines are human B lym-
phocytes immortalizedwith Epstein-Barr virus. TheT2 cell line
is a humanT cell leukemia/B cell line hybrid defective in TAP1/
TAP2 (transporter associated with antigen presentation) and
1i/5i subunits. The T2 cell line contains only standard pro-
teasome (s-proteasomes), whereas the lymphoblastoid cell line
possesses proteasomes carrying mainly immuno-subunits, and
it is namedhere as immunoproteasome (i-proteasome) (14, 25).
Peptides and Peptide Synthesis—The sequence enumeration
for the polypeptides gp100201–230 (AHSSSAFTITDQVPFSVS-
VSQLRALDGGNK) and mutgp100201–230 (AHSSSAFTIM-
DQVPFSVSVSQLRALDGGNK) is referred to the human pro-
tein gp100PMEL17. All peptides were synthesized using Fmoc
(N-(9-fluorenyl)methoxycarbonyl) solid phase chemistry as
previously described (26). The purity of synthetic peptides was
tested by amino acid analysis (3).
20S Proteasome Purification—20S proteasomes were puri-
fied from T2 and the lymphoblastoid cell lines as previously
described (26). Purity of the preparation is depicted in Fig. 8.
In Vitro Digestion of Synthetic Peptides by 20S Proteasomes
and Recombinant ERAP1—Synthetic polypeptides (40 M)
were digested by 3 g of 20S proteasomes in 100 l of TEAD
buffer (20 mM Tris, 1 mM EDTA, 1 mM NaN3, 1 mM DTT, pH
7.2) over time (0–4 h) at 37 °C.
50 M concentrations of the peptides wtgp100209–217,
wtgp100208–217, wtgp100207–217, wtgp100206–217, wtgp100205–217,
mutgp100209–217, mutgp100208–217, and mutgp100207–217 were
digested in vitro by 2.5 ng of recombinant ERAP1 (recombinant
human aminopeptidase PILS/ALAP/ERAP1; R&D Systems) in
20 l of assay buffer (25 mM Tris, pH 7.5, 150 mM NaCl, 0.5
g/ml albumin) at 37 °C over time. To test the ERAP1 depen-
dence of the reaction, 3 ng of recombinant ERAP1 were incu-
bated in buffer in the presence of 30 M leucinethiol (27) at
room temperature for 20 min before co-incubation with the
gp100 synthetic peptides. A reduction of 60% of ERAP1 activity
was observed (data not shown).
Quantification of Peptides and Substrate Site-specific Cleav-
age Strength (SCS) Computation—Liquid chromatography
mass spectrometry (LC-MS) analyses of polypeptide digestion
products were performed as previously described (28) by the
ESI-ion trap instrument DECA XP MAX (ThermoFisher Sci-
entific). Database searching was performed using SpliceMet’s
ProteaJ, which allowed the identification of spliced and non-
spliced peptide products (28). Quantification of proteasome-
generated non-spliced and spliced peptides and computation of
the SCS was carried out by applying the QME (Quantification
with Minimal Effort) method to the LC-MS analyses (3). QME
estimates the absolute content of spliced and non-spliced pep-
tide products based on their MS ion strength measured in the
digestion probe. QME is an optimization tool that makes use of
the law of mass conservation and MS instrument features. For
example it considers the dependence of the MS ion strength of
a given peptide on the peptide sequence and length. The QME
algorithm parameters were empirically computed in our previ-
ous study (3) and were applied here. SCS describes the relative
frequencies of proteasome cleavage after any given residue of
the synthetic polypeptide substrates (3). The SCS value showed
in this study are the average of SCS measured over time (3).
In the in vitro digestion of the gp100-derived peptides by
recombinant ERAP1 we did not apply QME because the low
molecular N-terminal trimmed peptides cannot be detected by
LC-ESI-MS. Therefore, we performed a canonical titration of
the digestion products using synthetic peptides as previously
described (28). In particular, synthetic peptides were mixed
with 15 ng of inactive recombinant ERAP1 in 100 l of diges-
tion buffer, their precursor ion intensity was measured in trip-
licate by LC-MS, and the derived linear titration curves were
used to calculate the pmol of trimmed fragments in the in vitro
ERAP1 digestion over time.
MHC Class I-Peptide Complex Binding Affinity and Sta-
bility—Stability of the HLA-A*02:01-peptide complex was
determined by pulsing of 105 T2 cells (HLA-A*02:01) for 16 h
by synthetic peptides at concentrations exhibiting the largest
binding efficiency, i.e. 100 M (data not shown). Afterward,
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cells were washed twice, and the expression of the HLA-
A*02:01 at the cell surface was measured over time by FACS
analysis using FITC mouse anti-human HLA-A*02 antibody
(1:100, BD Bioscience). The stability of the complex MHC-
epitope is expressed by its half-life (t1⁄2) at the cell surface and
was calculated as t1⁄2 ln(2)/k. kwas estimated byminimization
of the equation C  C0 exp(kt), where C is the signal over
time, C0 is the signal measured at time 0, and t is the time.
Therefore, k describes the rate of the exponential decay of the
complex MHC-epitope.
The binding affinity of the epitope wtgp100213–218/220–222 to
the HLA-B*07:02 complex was measured in classical competi-
tion binding assays utilizing purified MHC and a high affinity
radiolabeled ligand, as previously described (29). Under the
conditions utilized for these assays, where [label] [MHC] and
IC50 [MHC], the measured IC50 values represent reasonable
approximations of trueKd values (30). Each competitor peptide
was tested in 3 or more independent assays at 6 different con-
centrations covering a 100,000-fold dose range.
The binding affinity of thewhole pool of 8–12-mer spliced or
non-spliced peptides identified in the proteasome digestions
were evaluated for their predicted binding affinity to the most
frequent HLA-A and -B haplotypes (i.e. HLA-A*01:01, -A*02:
01, -A*03:01, -A*24:02, -A*26:01, -B*07:02, -B*08:01, -B*27:05,
-B*39:01, -B*40:01, -B*58:01, -B*15:01) by using the ANN-Net-
MHC prediction software version 3.4 (31). In the analysis we
included all 8–14-mer peptides produced by proteasome and
allowed only N-terminal trimming of the peptides to generate
the binder peptides. Because the high inter-experimental vari-
ability of the MHC class I- peptide stability assay depended on
technical factors (the same antigen presenting cells (APCs) and
peptides are used in all assays), we reported in Fig. 6A the S.E.
instead of the S.D.
CTL Assay—CTL assays were performed with peripheral
blood lymphocytes (PBLs) of a healthy donor transduced with
gp100mel209–217 epitope-specific T cell receptor, which was
generated as described elsewhere.4 As APCs, we used the K652
cell line transduced withHLA-A*02:01, which does not express
otherHLAcomplexes. APCswere pulsed for 2 h at 4 °Cwith the
synthetic peptides, washed twice, and co-cultivated with the
transduced PBLs for 16 h. The specific response of transduced
PBLs against APCs pulsed with different concentrations of the
epitopes were measured by IFN- release, which was deter-
mined using a commercially available human ELISA kit (BD
Biosciences) according to the manufacturer’s instructions. The
EC50 (concentration of peptide triggering half of the measured
maximal PBL response) was computed by linear interpolation
of the values IFN- versus peptide amount (Fig. 6B) in proxim-
ity of half of the measured maximal PBL response. Because the
high inter-experimental variability of the IFN- release abso-
lute amount in the CTL assay depended on technical factors
(the same CTL clone and APCs are used in all assays), we
reported in Fig. 6B the S.E. instead of the S.D.
Results
A Single Thr/Met Substitution in the Polypeptide gp100201–230
Affects Cleavage Site Usage—Assessment of the impact of a
mutation within an antigen on its cleavage-site usage by 20S
proteasomes requires a method permitting comparison of the
quality and quantity of the digestion products derived from
both wild type (wt) and mutated (mut) synthetic gp100201–230
polypeptides. Previous approaches considered only a portion of
the entire product pool and used the MS fragment ionization
intensity as a surrogate marker for quantity (16). However, this
approach is not applicable when peptides of different lengths
are analyzed (3). To solve these caveats and limitations we ap-
plied the QME method for quantitative analysis (3). QME
allows quantification of the amount of each product of a pro-
teasome digestion identified by MS analysis and computation
of the cleavage site usage, i.e. the SCS. Importantly, QME fea-
tures also allow minimizing the impact of the difference in MS
ionization of wt andmut peptides in determining their amount
in the digestion sample (see “Experimental Procedures”). A
mutation introduced in an antigen sequence might change the
quality of the peptide pool generated upon proteasome diges-
tion of the antigen. In addition, the digestion products gener-
ated by cleavage at the same sites of the wt and mut substrates
may differ in their sequence if the mutation is within the sub-
strate cleavage sites (Fig. 1). Both aspects might temper the4 F. Ebstein et al., personal communication.
FIGURE 1.gp100 T210M substitution alters the product peptide pool. Schematic representation of the number of common or specific peptides generated
by 20S proteasomes by cleaving in vitro the synthetic substrates wtgp100201–230 or mutgp100201–230.
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correct quantitation of the SCS and of the product’s amount by
QME and were thus tested.
In fact, upon processing of the synthetic wtgp100201–230 or
mutgp100201–230 polypeptides by 20S s- and i-proteasomes, we
identified 94 peptide products (10 spliced peptides) and 93
products (5 spliced peptides), respectively (Fig. 1). In agreement
with our previous results (14), the peptide pools produced by
both s- or i-proteasomes perfectly overlapped with respect to
numbers and sequences of the products (data not shown). 56
products (2 spliced peptides, i.e. gp100201–204/201–209 and
gp100205–210/214–217) were generated from both wt and mut
substrates. Hence, the T210M substitution led to a variation of
the pool of in vitro generated peptides by 20S proteasomes of
40% (Fig. 1).
For initial validation of our quantitative approach we applied
QME to the MS dataset containing only the 56 peptides com-
mon towt andmut substrate digestions.We then compared the
resulting SCS with the SCS computed by applying QME to
the full peptide datasets of either the wtgp100201–230 and
mutgp100201–230 substrate digestion. By adopting this strategy
we could understand whether the difference in the substrate
cleavage-site usage introduced by the T210M substitution
depended only on the peptides specific to wt and mut sub-
strates. The wt and mut substrate SCSs computed by applying
QME to full peptide (i.e. 94 and 93 peptides) or to the common
peptide (i.e. 56 peptides) datasets did not dramatically differ
(Fig. 2, A and B). This indicates that the peptides common to
wtgp100201–230 and mutgp100201–230 substrate digestions were
FIGURE 2.Product peptides specific forwt ormutgp100201–230 substrate degradationonlymarginally influence the substrate cleavage-site usageby
proteasome. The SCSs of the wt or mut gp100201–230 substrate computed by QME considering the full products pool or only the peptides common to both
substrates is shown. The analysis is performed for both s- (A) and i- (B) proteasome digestions. Histograms represent the mean of four time points, and bars
represent the S.D. of three independent experiments measured in duplicate. C, quantitative kinetics of the representative peptide products gp100201–209,
gp100201–226, and gp100221–230 calculated by applying QME to the full or the common peptide pools of the wt andmut gp100201–230 substrate digestion. No
major difference in the absolute amount of each peptide was observed between the analysis done with full or the common peptide pools. It proves that the
QME method can be applied to this study and does not introduce artifacts due to the difference in the database size. The peptides represent the N- and
C-terminal area of the substrates (gp100201–209 and gp100221–230) and two different peptide sizes (gp100201–226 versus gp100201–209 and gp100221–230). We
chose these peptides as controls because both the location and the length of the peptide products are relevant in the QME computation of the peptide
absolute amount (3). Only the results obtained from s-proteasome-mediated degradation are shown.
FIGURE 3. gp100 T210M substitution alters the substrate cleavage-site usage by 20S proteasomes. The SCS by s- (A) and i- (B) proteasomes of the
synthetic substrates wtgp100201–230 or mutgp100201–230. SCS was computed by QME from kinetics experiments. Histograms represent the mean of four time
points, and bars represent the S.D. of three independent experiments measured in duplicate.
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the most frequently generated peptides and represent the core
of the peptide pools. The analysis of the quantitative kinetics of
representative peptides verified that the QME calculation was
remarkably unbiased by the size of theMSdatasets compared in
this study. These peptides, one long product (26-mer) and two
9-mers located at the N and C termini of the substrates, were
chosen to test potential bias of QME calculation for peptides of
different length or position within the wt and mut gp100 sub-
strates (Fig. 2C). Thus, all controls supported the use of QME
on the wt and mut peptide datasets to evaluate the effect of the
substitution.
When we compared the SCSs based on the common peptide
datasets of the wtgp100201–230 and mutgp100201–230 substrate
digestions, we observed that the T210M substitution strongly
altered the frequency of cleavage after several substrate resi-
dues even distant to the substitution site such as the sites His-
202, Val-217, Leu-222, and Leu-225 (Fig. 3). Of note, the
T210M substitution did not significantly altered the preference
of s- or i-proteasomes for specific substrate sites (Fig. 4) previ-
ously identified (14).
gp100201–230 T210M Substitution Affects the Generation of
Non-spliced Antigenic Peptides—Our study also showed that
theT210Msubstitution altered not only the substrate cleavage-
site usage but also the quality and quantity of the potential
MHC class I-restricted pool of antigenic peptides by affecting
their kinetics and/or their overall generation (Table 1). For
instance, the synthetic substrate wtgp100201–230 contains the
well known HLA-A*02:01-restricted wtgp100209–217 epitope
(24). As observed before for the wtgp100209–217 epitope (14, 32),
the mutgp100209–217 epitope was also not generated by the 20S
proteasome as such but was generated as N-terminally
extended precursor peptides (data not shown). In fact, from the
wtgp100201–230 substrate we obtained the N-terminally ex-
tended peptides wtgp100208–217, wtgp100207–217, wtgp100206–217,
and wtgp100205–217, whereas from the mutgp100201–230
substrate the elongated peptides mutgp100208–217 and
mutgp100207–217 were produced by the 20S proteasome (Fig.
5A). Only the generation kinetics of the wtgp100206–217 peptide
was influenced by the proteasome isoform used in the assay
(Fig. 5A).
FIGURE 4.gp100 T210Mmutation does not impinge upon the s- and i-proteasome usage of the preferential substrate cleavage sites. The SCSs of
the synthetic wtgp100201–230 (A) and mutgp100201–230 (B) substrates by s- and i- proteasomes is compared. The cleavage sites that we previously
described as significantly more used by i-proteasome (i.e. gp100 Ile-209, Val-219, and Leu-222) or s-proteasome (i.e. gp100 Val-213, Ser-220, and
Asp-226) (14) are consistently preferred during the digestion of wt or mut gp100201–230 substrates. SCSs are computed by applying QME on kinetics
experiments. Histograms represent the mean of four time points, and bars represent the S.D. of three independent experiments measured in
duplicate.
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Although the substrate degradation rate was not affected by
the T210M substitution (Fig. 5A), the T210M substitution
affected the production of the N-terminally extended precur-
sors of the epitope mutgp100209–217. In comparison to the wild
type counterparts the Thr/Met residue exchange abolished the
production of the peptides mutgp100206–217 and mutgp100205–217
and improved the generation of the peptides mutgp100208–217
and mutgp100207–217 regardless of which proteasome isoform
was used in the assay (Fig. 5A). We can exclude that the pep-
tides mutgp100206–217 and mutgp100205–217 were not detected
due to a sequence-dependent lower MS ion signal of the
mutated peptides because the intensity of theMS ion signals of
the synthetic wt and mut peptides were comparable (data not
shown).
Theoretically, all the identified N-terminally extended pre-
cursors peptides may be further trimmed by ERAPs to produce
the epitope. As shown in Fig. 5B, in vitro the trimming of the
N-terminally extended peptides wtgp100208–217, wtgp100207–217,
wtgp100206–217, and wtgp100205–217 as well as mutgp100208–217
and mutgp100207–217 was catalyzed by recombinant ERAP1.
Trimming by ERAP1 stoppedwhen theminimal antigenic pep-
tides wtgp100209–217 and mutgp100209–217 were generated (data
not shown). No effects of the T210M substitution were
observed in the ERAP1-dependent kinetics of peptide genera-
tion (Fig. 5B).
Previous studies focused on MHC class I-restricted epitopes
documented antigenic peptides longer than the canonical 8–
9-mers presented onto MHC class I complexes and able to
elicit CD8 T cell response (33–36). Thus, the N-terminally
extended peptides of the epitopes wtgp100209–217 and
mutgp100209–217 may not only be precursors of the 9-mer
epitopes but also exhibit sufficient affinity by themselves to
bind the HLA-A*02:01 complex. To test this hypothesis, we
measured in vitro the stability of the HLA-A*02:01-peptide
complex of the two wt and mut gp100207–217 (11-mer) and
gp100208–217 (10-mer) precursor peptides generated by the 20S
proteasome and of thewt andmut gp100209–217 9-mer epitopes
produced by ERAP1-catalyzed trimming. Both wt and mut
gp100207–217 and gp100208–217 peptides exhibited sufficient
affinity for binding the HLA-A*02:01 molecules, although the
formed MHC class I-peptide complexes were less stable than
those formed with the 9-mer peptides (Fig. 6A). As expected,
the stability of the HLA-A*02:01-peptide complex was consid-
erably improved by the T210M substitution. In fact, the
Thr/Met exchange enhanced the binding of the 11-mer
mutgp100207–217 and 10-mer mutgp100208–217 peptides that was
more stable than the ones formed with the wtgp100209–217
epitope (Fig. 6A).
These data suggest that the proteasome-generated N-termi-
nally extended peptides may not only be a source for the
production of the known epitopes wtgp100209–217 and
mutgp100209–217 butmight also be able to elicit a CTL response.
To test this hypothesis, we performed CTL assays with
gp100209–217-specific CD8 T cells exposed to HLA-A*02:01
APCs pulsed with different concentrations of the synthetic wt
and mut gp100207–217 11-mer, gp100208–217 10-mer, and
gp100209–217 9-mer peptides. In agreementwith theMHCclass
I-peptide stability assays, the wtgp100209–217 and mutgp100209–217
epitopes triggered a stronger CTL response than theirN-termi-
nally extended versions, although the mutgp100208–217 and
mutgp100207–217 epitopes elicited a CTL response similar or
even stronger than the wtgp100209–217 epitope (Fig. 6B).
TABLE 1
8–12-mer peptides that potentially bind the most frequent HLA-A and -B haplotypes and are produced by proteasome-catalyzed digestion of
thewt and/ormut gp100201–230 polypeptides
Thenon-spliced and spliced 8–12-mer peptides shownwere produced by proteasomal processing of thewt and/ormut gp100201–230 polypeptides as such or asN-terminally
extended precursors. Binding affinities of the peptides were predicted in silico by using ANN-NetMHC software version 3.4 (31). We included in the analysis the most
frequent HLA-A and -B haplotypes (i.e., HLA-A*01:01, -A*02:01, -A*03:01, -A*24:02, -A*26:01, -B*07:02, -B*08:01, -B*27:05, -B*39:01, -B*40:01, -B*58:01, -B*15:01). Only
8–14-mer peptides were used for the in silico analysis, and only N-terminally extended peptides were considered as MHC class I binder precursors (i.e. the binder and the
precursor peptides must have the same C terminus). Only 8–12-mer peptides with predicted IC50 values 200 nM were considered as efficient binders. In the peptide
sequence the T210M is marked in bold. When both wt and mut peptides were produced by proteasome and predicted to be MHC class I binders, we reported the wt
sequence and the substitution as following T(M).When both wt andmut peptides had a IC50 200 nMwe stated whether the IC50 was affected by the T210M substitution.
Precursors (gp100_) Binder (gp100_) Sequence HLA-
IC50 influenced by
T210M substitution?
8–12-Mer peptide binders common to wt and mut gp100201–230-produced peptide pool
201–209 202–209 HSSSAFTI B*58:01 No
208–217 209–217 IT(M)DQVPFSV A*02:01 Yes
201–209 201–209 AHSSSAFTI B*39:01 No
205–215 207–215 FTIT(M)DQVPF B*15:01, B58:01 Yes
208–217 208–217 TIT(M)DQVPFSV A*02:01 Yes
207–217 207–217 FTIT(M)DQVPFSV A*02:01 Yes
205–215 205–215 SAFTIT(M)DQVPF B*15:01 Yes
8–12-Mer peptide binders unique for the wtgp100201–230-produced peptide pool
208–219 208–219 TITDQVPFSVSV A*02:01
210–218/220–222 213–218/220–222 VPFSVSSQL B*07:02
201–207/201–207 207/201–207 FAHSSSAF B*15:01
201–207/201–207 206–207/201–207 AFAHSSSAF B*15:01
201–207/201–207 205–207/201–207 SAFAHSSSAF B*15:01
201–207/201–207 204–207/201–207 SSAFAHSSSAF B*15:01
201–207/201–207 203–207/201–207 SSSAFAHSSSAF B*58:01
210–212/214–222 212/214–222 QPFSVSVSQL B*39:01
8–12-Mer peptide binders unique for the mutgp100201–230-produced peptide pool
205–215 208–215 TIMDQVPF B*15:01
201–204/201–207 204/201–207 SAHSSSAF B*15:01
201–204/201–207 203–204/201–207 SSAHSSSAF B*15:01
201–204/201–207 202–204/201–207 HSSAHSSSAF B*15:01
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gp100201–230 T210M Impinges upon theGeneration of Spliced
Epitope Precursors—The second group of peptides of interest
are the spliced peptides, which are generated by proteasome-
catalyzed peptide splicing, whose immunological relevance has
been emerging in the past years. We found that the T210M
substitution strongly affected the generation of such peptides; 8
out of 10 spliced peptides were generated only from the
wtgp100201–230 substrate, whereas 3 out of 5 spliced peptides
were generated exclusively from the mutgp100201–230 substrates
(Fig. 1). Among the spliced peptides only generated from the
wtgp100201–230 substrate, five were potential precursors of pre-
dicted HLA-A or -B binders (predicted IC50  200 nM). For
instance, thepeptidesgp100210–218/220–222 andgp100210–212/214–222
were produced by cis proteasome-catalyzed peptide splicing; the
peptide gp100210–218/220–222 was trimmed in vitro by ERAP1,
thereby generating the antigenic peptide gp100213–218/220–222
[VPFSVS][SQL] (Fig. 7, A and B), which efficiently binds the
HLA-B*07:02 complex (IC50, 28 nM; Fig. 7C); the peptide
gp100210–212/214–222 might be trimmed up to produce the pep-
tide gp100212/214–222, which was predicted to efficiently bind
FIGURE 5. gp100 T210M substitution alters the generation of the gp100209–217 epitope and its N-terminally extended peptides. A, proteasome-
mediated generation; quantitative kinetics of the wtgp100201–230 and mutgp100201–230 substrate degradation and of the production of the peptides wt
gp100205–217 and gp100206–217 as well as the wt and mut gp100207–217 and gp100208–217 peptides from the carried out by 20S s- and i-proteasomes. Peptide
amount values are the means, and bars are the S.D. of three independent in vitro experiments. B, ERAP1-mediated trimming; quantitative kinetics of the
substrates wtgp100205–217 and wtgp100206–217 (upper panels) or wt and mut gp100207–217 and gp100208–217 (lower panels) trimmed by recombinant ERAP1.
Peptide amount values are the means, and bars are the S.D. of three independent in vitro experiments.
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the HLA-B*39:01 complex (Table 1). In contrast, the spliced
peptides gp100201–207/201–207 and gp100201–209/201–207, both
representing potential precursors of the HLA-B*15:01-binding
antigenic peptides gp100207/201–207 (and N-extended variants)
and gp100209/201–207 (and N-extended variants), respectively,
were produced by trans proteasome-catalyzed peptide splicing
(Table 1 and data not shown). However, because trans pro-
teasome-catalyzed peptide splicing seems to occur with low
efficiency in cells (1), these spliced peptides appear to be less
relevant from the immunological point of view. The same
applies for the trans spliced peptide gp100201–204/201–207,
i.e. the precursor of the antigenic peptide gp100203–204/201–207,
which is specific for the substrate mutgp100201–230 (Table 1).
The purity of the 20S proteasome preparation (Fig. 8) excluded
that the peptide splicing reaction observed in our assays could
be catalyzed by other proteases.
Discussion
Increasing evidence suggests that tumor-specific somatic
mutations enhancing the MHC class I binding affinity of an
antigenic peptide are potentially the best targets for adoptive T
cell therapy of established tumors (22). However, factors like
processing of a tumor antigen by proteasomes, trimming of
antigenic precursor peptides by ERAPs, and binding of peptides
toMHC class I with sufficient affinity will determine whether a
given peptide may be a suitable therapeutic target. Very little is
known about how such mutations within a tumor epitope
sequence will affect proteasomal processing of the respective
antigen and in consequence the generation of the mutated
epitope. In the present communication we, therefore, analyzed
the effect of the experimentally introduced T210M amino acid
exchange within themelanoma antigen-derivedHLA-A*02:01-
restricted gp100209–217 epitope on proteasomal processing of
the gp100201–230 polypeptide. This antigenic peptide was cho-
sen as a suitablemodel antigen because the T201M exchange at
the anchor position of the epitope increased its MHC binding
affinity as well as its immunogenicity (24) thereby exhibiting
two features that are mandatory for peptide targets suited for T
cell therapy.
To study the impact of the T201M exchange within the
gp100209–217 epitope, we developed a novel biochemical
method for the quantitative evaluation of the effect of a muta-
tion on the processing of a given substrate and connected it
with the generation and presentation of antigenic peptides on
the MHC class I molecules. The previous pioneering study by
Tenzer et al. (16), which challenged a similar issue and carried
out a quantitative evaluation of the effect of HIV mutations on
antigen presentation, had some caveats and limitations regard-
ing the quantification of the in vitro products of proteasomal
digestions and the computation of the substrate cleavage site
usage. Such restrictions have been solved using the recently
developed QME method (3). By applying this method we
assessed how the T210M substitution influenced the wt and
mut gp100201–230 substrate cleavage site usage by proteasomes.
Our quantitative analysis shows that the substitution not only
affects the cleavage site usage by the proteasome close to the
substitution but also major cleavage sites as distant as 15 resi-
dues away from the substitution. The influence of a givenmuta-
tion on cleavages that are four-five residues apart from the site
of the mutation might be explained by a mutation-induced
alteration of substrate binding to the S4-S1 and S1-S4 sub-
FIGURE 6. Presentation to and recognition by CD8 T cells of the gp100209–217 epitope and its N-terminally extended peptides is affected by the
T210M substitution. A, binding to the HLA-A*02:01 molecule; the stability of the complex MHC class I bound to the wt andmut gp100207–217, gp100208–217,
and gp100209–217 peptides is shown. The MHC class I-peptide stability was measured by pulsing the synthetic peptides onto T2 cells (expressing the HLA-
A*02:01molecule) over time and by assessing theHLA-A*02:01 expression on the cell surface by FACS analysis. The t1⁄2 of the HLA-A*02:01-peptide is reported
in the panel. Values are themean, and bars are the S.E. of two independent experimentsmeasured in duplicate. FU, fluorescence unit. B, CTL response; IFN- release
by gp100209–217-specific PBLs triggered by HLA-A*02:01-expressing K652 cells pulsed with synthetic peptides. The EC50 (concentration of peptide triggering
half of themeasuredmaximal PBL response) is reported in the right panel. Values are themeans, and bars are the S.E. of independent experiments (n 5–16)
measured in duplicate.
gp100 T210M Substitution Affects Antigen Processing
DECEMBER 18, 2015•VOLUME 290•NUMBER 51 JOURNAL OF BIOLOGICAL CHEMISTRY 30425
 at Im
perial College London on July 22, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
strate-binding sites of the proteasome’s catalytic pockets (37).
On the contrary, the effects on the substrate cleavage site usage
that are 15 residues apart form the T210M exchange are more
difficult to assess and may be due to alterations of substrate
transport along the proteasome cavities or the binding to non-
catalytic modifier sites (38–41).
As observed in the in vitro experiments, the gp100 T210M
substitution also resulted in a surprising and substantial alter-
ation of the peptide pools produced by the 20S proteasome.The
fact that the gp100 T210M substitution results in the genera-
tion of 37 unique non-spliced and 3 unique spliced peptides and
that this pool contains potential antigenic peptides, which are
not generated from the wt substrate (Table 1) indicates that
tumor-specific somatic mutations may also induce the genera-
tion of new epitopes located not too far from the mutation.
Although such epitopes do not carry somatic mutations, they
would be tumor-specific and thus represent potential targets
for specific adoptive T cell transfer therapy.
Our quantitative analysis of the post-proteasomal antigen
presentation steps also revealed some interesting aspects of the
potential immune relevance of N-terminally extended epitope-
precursor peptides. Probably the most relevant result of these
analyses is that mutations at the anchor position of an epitope
that increase the MHC class I binding affinity of the minimal
epitope peptide can also enhance theMHCclass I binding affin-
ity of N-terminally elongated variants of the minimal epitopes.
In consequence, mutant N-terminally extended variants of the
minimal epitopes may be presented on the cell surface as effi-
ciently as the wtminimal epitope (e.g. wtgp100209–217) and trig-
ger a specific CD8 T cell response. These results also indicate
that even when proteasomes generate the 9-mer epitope,
ERAPs can trim proteasome-generated N-terminally extended
precursor peptides (12-mers) thereby producing 10–12-
mers (or longer) that will bind efficiently theMHC class I com-
plex and thus may contribute directly to the CD8 T cell
response.
In summary, our quantitative analyses of the main steps in
antigen processing suggest that tumor-specific somatic muta-
tions increasing the MHC class I binding affinity of an epitope
may also broaden the specific T cell response by enhancing the
FIGURE 7. Quantitative kinetics displaying the processing of the spliced
peptide gp100210–218/220–222 by 20S proteasomes and ERAP1. A, protea-
some-mediated generation kinetics of the peptide gp100210–218/220–222 from
the wt and mut gp100201–230 substrate digestions carried out by 20S s- and
i-proteasomes. Peptide amount values are themeans, and bars are the S.D. of
three independent in vitro experiments. B, ERAP1 trimming kinetics of the
substrate wtgp100210–218/220–222. No products shorter than the HLA-B*07:02-
restricted epitope wtgp100213–218/220–222 were detected in the assay. Peptide
amount values are the means, and bars are the S.D. of three independent in
vitro experiments. C, binding to the HLA-B07:02 molecule by the epitope
wtgp100213–218/220–222 (IC50 28 nM).
FIGURE8.Purityof20Sproteasomepreparation.20Sproteasomespurified
from T2 and lymphoblastoid (LcL) cell lines (1 g) were separated by SDS-
PAGEand stainedbyCoomassie Blue todetect possible contaminations.Only
the characteristic bands of 20S proteasome, with sizes between 21 and 31
kDa, are visible, confirming the high purity of the proteasome preparation.
For instance, no contamination with Hsp molecules at high molecular mass
(above 60 kDa), which are often present in less pure proteasome prepara-
tions, could be detected.
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presentation of immune reactive N-terminally extended pre-
cursor peptides. Furthermore, mutations may affect the gener-
ation of new unpredicted non-spliced and spliced epitopes,
whichwill be of particular relevancewhenmutant polypeptides
are used as tumor vaccines to improve the immune response.
The impact of a tumor-specific somaticmutation could interest
several immunogenic peptides located in proximity of the
mutation, and only a systemic and quantitative biochemical
study could estimate the outcome from an immunological
point of view.
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